| 75.2 | ug/mL | CD54, EC200 | Dermal | - | NTP_ICE_skin_sensitization |
| 5.8 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 6.2 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 76 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 24.06 | ug/mL | CV70 | Dermal | - | NTP_ICE_skin_sensitization |
| 254.8 | ug/mL | CV75 | Dermal | - | NTP_ICE_skin_sensitization |
| 255 | ug/mL | CV75 | Dermal | - | NTP_ICE_skin_sensitization |
| 9.1 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 39.4 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 3.4 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 6.3 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 7.7 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 21.4 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 71.84 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| 79.6 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| 17 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 17 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 17 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 17 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 200.3 | uM | EC3 | Dermal | - | NTP_ICE_skin_sensitization |
| QUE43B9Z2Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| QUE43B9Z2Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| QUE43B9Z2Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| QUE43B9Z2Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 355.4 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 428.65 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 16.1 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| 20.31 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| - | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 775 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 3100 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 6750 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 8264 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| =0.02 | % | NOAEL | - | - | SCCS_vision_codex |
| =0.02 | % | NOAEL | - | - | SCCS_vision_codex |
| =0.02 | % | NOAEL | - | - | SCCS_vision_codex |
| =0.02 | % | NOAEL | - | - | SCCS_vision_codex |
| =4000 | µg/cm2 | NOAEL | - | - | SCCS_vision_codex |
| =4000 | µg/cm2 | NOAEL | - | - | SCCS_vision_codex |
| =4000 | µg/cm2 | NOAEL | - | - | SCCS_vision_codex |
| =4000 | µg/cm2 | NOAEL | - | - | SCCS_vision_codex |
| 3 | unitless | Relative reliability score | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.02 | % | sensitisation | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4000 | µg/cm2 | sensitisation | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |